Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Bladder Cancer. Version 3.2020
Thomas W. Flaig et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial
Rongxin Li et al.
BMC UROLOGY (2020)
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update
Marko Babjuk et al.
EUROPEAN UROLOGY (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
The efficacy and safety of intravesical gemcitabine vs Bacille Calmette-Guerin for adjuvant treatment of non-muscle invasive bladder cancer: a meta-analysis
Ziqi Ye et al.
ONCOTARGETS AND THERAPY (2018)
Defining Progression in Nonmuscle Invasive Bladder Cancer: It is Time for a New, Standard Definition
Donald Lamm et al.
JOURNAL OF UROLOGY (2014)
Intravesical gemcitabine for non-muscle invasive bladder cancer
Gabriel Jones et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2012)
Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: A phase I and pharmacokinetic study
M Laufer et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Selective cytotoxicity of gemcitabine in bladder cancer cell lines
R Kilani et al.
ANTI-CANCER DRUGS (2002)
Chemotherapy and management of bladder tumours
CN Sternberg et al.
BJU INTERNATIONAL (2000)
Share Paper
